Sign in to view content

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial

Diana V Do, MD, FASRS

Video
Published 2024

Related

Plasma Arginine and Citrulline are Elevated in Diabetic Retinopathy
Milam A. Brantley, MD, PhD
On Demand Cases, Courses, and Papers
2019
Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023
The Conundrum of Intravitreal Injections and Use of -25 Modifier for Same-Day Office Visits
John T. Thompson, MD
Annual Meeting Talks
2021

Category: Retinal Vascular Disease

See more